Pramipexole API manufacturers
compare suppliers & send inquiries for free
Country of origin
Established in: 2005
Portfolio of over 2,000 APIs
Precise quality control
End-to-end global regulatory support
Established in: 1885
MOQ: 1000 kg
Trusted for 140 years
Global distribution business with API manufacturing facilities
European company with presence in 3 continents
Established in: 1991
More than 12 GMP manufacturing facilities (EU, US, India)
Portfolio of more than 240 commercial APIs
We are experts in the cGMP production of highly potent compounds
How does it work?
You can register for free as long as you are registering on behalf of a legal company related to the pharmaceutical industry
Search in the search bar the product that you’re looking for. We’ll show you an overview of all available suppliers. Use the filters to select the relevant suppliers only
Have you found interesting suppliers? Then it’s time to contact them. Use the send inquiry button and send them a message. You can send for each product, 3 inquiries per week
Suppliers get notified by Pharmaoffer that they’ve received a new inquiry. They will come back to you with their questions, certificates, and offer in the chat on Pharmaoffer. We will send you an email in case of any news
Does the supplier meet your quality and commercial requirements? Then you can place the order. Just follow the steps of our order module
Looking for Pramipexole 104632-26-0?
- Here you will find a list of producers, manufacturers and traders of Pramipexole. You can sort by certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Pramipexol , Pramipexole , Pramipexolum , Pramipexole dihydrochloride monohydrate
- Cas Number:
- DrugBank number:
- Unique Ingredient Identifier:
What makes Pramipexole unique? Pramipexole is a drug used to treat the symptoms of Parkinson's Disease (PD). It is a non-ergot dopamine agonist drug that is efficacious in treating various Parkinson's symptoms such as tremor, rigidity, and bradykinesia (slow movement) It was first approved by the FDA in 1997 Parkinson's Disease is one of the most common neurodegenerative disorders and causes a high level of disability in patients leading to increased difficulty in performing activities of daily living due to symptoms that progress over time The prevalence of Parkinson's Disease worldwide has increased from approximately million in 1990 to about million in 2016 This increase may be attributed to an aging population along with other contributing factors In addition to the above FDA approval for Parkinson's Disease, pramipexole was also approved by the FDA in 2006 for the treatment of Restless Legs Syndrome (RLS).
You can find more info about this product by clicking on the DB ID above.
Pramipexole is a type of Dopamine agonists
Dopamine agonists are a subcategory of pharmaceutical active pharmaceutical ingredients (APIs) that act on the dopamine receptors in the brain. These compounds mimic the effects of dopamine, a neurotransmitter involved in various physiological processes such as movement, cognition, and emotions.
Dopamine agonists are commonly used in the treatment of neurological disorders, particularly Parkinson's disease and restless legs syndrome. They work by binding to dopamine receptors and stimulating them, thereby increasing dopamine activity in the brain. This helps to alleviate the symptoms associated with these conditions, such as tremors, rigidity, and muscle stiffness.
One of the key advantages of dopamine agonists is their ability to provide long-lasting relief compared to other medications. They are available in different formulations, including oral tablets, transdermal patches, and injectable solutions, allowing patients to choose the most suitable administration method.
However, like any medication, dopamine agonists may have side effects. These can include nausea, dizziness, hallucinations, and compulsive behaviors. It is important for healthcare professionals to closely monitor patients using dopamine agonists to minimize the occurrence and severity of these side effects.
In conclusion, dopamine agonists are a vital subcategory of pharmaceutical APIs used to manage Parkinson's disease and restless legs syndrome. They mimic the effects of dopamine in the brain and offer long-lasting relief from symptoms. Although they can have side effects, proper monitoring and dosage adjustments can help optimize their therapeutic benefits.
Pramipexole (Dopamine agonists), classified under Central Nervous System Agents
Central Nervous System (CNS) Agents are a crucial category of pharmaceutical Active Pharmaceutical Ingredients (APIs) that specifically target the central nervous system. The CNS encompasses the brain and spinal cord, playing a vital role in regulating and controlling various bodily functions, including cognition, movement, emotions, and sensory perception. These agents are designed to interact with specific receptors, enzymes, or ion channels within the CNS to modulate neural activity and restore normal functioning.
CNS agents comprise a diverse range of pharmaceutical APIs, including analgesics, anesthetics, antipsychotics, sedatives, hypnotics, anti-epileptics, and antidepressants. Each subcategory addresses distinct neurological disorders and conditions. For instance, analgesics alleviate pain by targeting receptors in the brain and spinal cord, while antipsychotics are employed to manage psychosis symptoms in mental illnesses such as schizophrenia.
The development of CNS agents involves rigorous research, molecular modeling, and extensive clinical trials to ensure safety, efficacy, and specific target engagement. Pharmaceutical companies invest significant resources in identifying novel drug targets, synthesizing new compounds, and optimizing their pharmacological properties. These agents undergo rigorous regulatory evaluations and must adhere to stringent quality standards and guidelines.
Given the prevalence of CNS disorders globally, the market demand for effective CNS agents is substantial. The development of innovative CNS APIs not only improves patient outcomes but also provides valuable commercial opportunities for pharmaceutical companies. Continued advancements in CNS agent research and development hold the promise of groundbreaking therapies that can improve the quality of life for individuals affected by neurological conditions.
Pramipexole manufacturers | traders | suppliers
We have 22 companies offering Pramipexole from 8 different countries.
Get in contact with the supplier of your choice:
- LGM Pharma from United States
- Chr. Olesen Group from Denmark
- Curia from United States
- Symbiotec Pharma from India
- Wockhardt from India
- Amino Chemicals from Malta
- Yonsung Fine Chem. from South Korea
- Torrent Pharma from India
- Unichem Labs. from India
- Sandoz from Austria
- Cadila Healthcare from India
- MSN Labs. from India
- Aurobindo from India
- Boehringer Ingelheim from Germany
- Hetero Drugs from India
- Alembic Pharma from India
- Erregierre from Italy
- Piramal Pharma Solutions from India
- Cipla from India
- Sun Pharma from India
- Mylan from India
- Piramal Healthcare from United Kingdom
Let the supplier know whether you are looking for a product with a specific monograph such as EP (Ph. Eur.), USP, JP, BP or another quality. Or, whether you are looking for hydrochloride (HCl), anhydricum, base, micronisatum or a specific purity.
You can use the filters to find high-quality suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our FAQ page or use the chat box in the corner to get more information about Pharmaoffer.